Compare Abbott Laboratories (ABT) vs Under Armour Inc Class A (UA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Under Armour Inc Class A — how do they compare? Abbott Laboratories trades at $95.29 (market cap $166.94B), while Under Armour Inc Class A trades at $6.32 (market cap $2.84B). The key difference: Abbott Laboratories is far larger — about 58.8× Under Armour Inc Class A's market cap, and Abbott Laboratories pays a 2.63% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| ABT | UA | |
|---|---|---|
Market Cap | $166.94B | $2.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $7.88 |
52-Week Low | $82.57 | $3.96 |
Enterprise Value | $193.69B | $4.47B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Under Armour (UA) trades at $6.64, up 2.47% with a bullish technical signal from moving averages despite bearish oscillators. The company reported mixed Q1 2026 results, missing EPS expectations after beating in previous quarters. Revenue declined to $5.0B in 2026 with a net loss of -$496M, though valuation remains reasonable with P/S of 0.57. Recent news highlights a Dodge collaboration and insider buying by Prem Watsa.
The outlook remains challenging with declining revenue and negative profitability, but analyst consensus leans positive with 40% buy ratings. Key risks include sustained revenue declines and competitive pressures, while potential catalysts include premium product focus and inventory discipline. The stock presents a turnaround opportunity with significant execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
